Across TCGA pan-cancer cohorts, GDAP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GDAP2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GDAP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GDAP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where GDAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	18	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LSCC	DFS	Quartile	All	0.784	0.265	.012	5	view →
OV	DFS	Quartile	All	0.592	1.000	.037	4	view →
GBM	OS	Quartile	All	0.458	0.631	.036	4	view →
LUAD	DFS	Median	All	0.837	0.446	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: GDAP2 tumor-vs-normal RNA expression · all GDAP2 data types